Glenmark Life Sciences Share Price
Small Cap | Pharmaceuticals and health care | NSE: ALIVUS | BSE: 543322
₹1,022.05 
-30.30 (-2.88 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 1,050.05
High (₹) 1,050.35
Low (₹) 1,001.10
Prev. Close (₹) 1,052.35
Volume 3,136
VWAP (₹) 1,027.28
ROCE (%) 26.24
Industry P/E 43.99
TTM P/E 28.35
P/B Ratio 5.34
Market Cap (₹) Cr.12,453.20
Dividend Yield (%)2.20
EPS (₹) 38.38
ROE20.16%
Sales Growth (%) 5.64
Profit Growth (%)0.84
Day Range
1,050.351,050.35
52 Week Range
666.051,335.00
Historical Returns
Returns (6M)
-1.11 %
Returns (1Y)
16.88 %
Returns (3Y)
112.42 %
Returns (5Y)
36.6 %
Returns (6M)
-1.11 %
Returns (1Y)
16.88 %
Returns (3Y)
112.42 %
Returns (5Y)
36.6 %
SWOT Analysis
- Growth in Net Profit Margin (QoQ)
- Growth in Annual Net Profit with increasing Profit Margin (YoY)
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
Technicals
Technical Rating
BEARISHRSI 46.35
MFI 30.93
ATR 64.75
Commodity Channel Index -93.30
ROC125 -2.84
ROC21 -11.65
Williams %R -89.92
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 1,044.66 | 1,072.13 | 1,093.91 | 1,022.88 | 995.41 | 973.63 | 946.16 |
| Week Ago | 1,050.60 | 1,088.30 | 1,115.60 | 1,023.30 | 985.60 | 958.30 | 920.60 |
| Month Ago | 1,213.44 | 1,278.42 | 1,342.04 | 1,149.82 | 1,084.84 | 1,021.22 | 956.24 |
EMA & SMA
1022.05
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
18
5 Day 1041.68
9 Day 1048.04
10 Day 1081.06
12 Day 1113.24
14 Day 1117.98
20 Day 1126.09
26 Day 1127.06
50 Day 1073.90
100 Day 1081.78
200 Day 1010.37
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BNP PARIBAS ARBITRAGE | block | Sell | 25 Jan, 2024 | ₹799.55 | 1,51,173 | BSE |
| SOCIETE GENERALE | block | Buy | 25 Jan, 2024 | ₹799.55 | 1,51,173 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 15 Jul, 2024 | Glenn Mario Saldanha | Disposal | ₹829.6251282051282051282051282 | 7,800 | BSE |
| 15 Jul, 2024 | Glenmark Pharmaceuticals Limited | Disposal | ₹830.7342995852780524749752096 | 96,09,571 | BSE |
| 13 Mar, 2024 | Nirma Limited | Acquisition | ₹598.5922740404322551303414936 | 2,45,05,435 | BSE |
| 13 Mar, 2024 | Glenmark Pharmaceuticals Limited | Disposal | ₹597.9936817689626811358378254 | 2,45,05,435 | BSE |
| 07 Mar, 2024 | Glenmark Pharmaceuticals Limited | Disposal | ₹597.9937559675075557267119854 | 6,73,89,944 | BSE |
| 25 Sept, 2023 | Glenmark Pharmaceuticals Limited | Pledge | ₹615.00 | 96,09,571 | BSE |
| 17 Nov, 2021 | GLENN SALDANHA | Acquisition | ₹643.1877415056628914057295137 | 7,505 | BSE |
| 17 Nov, 2021 | GLENN SALDANHA | Acquisition | ₹640.7661016949152542372881356 | 295 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 04 Oct, 2023 | Rs.22.5000 per share(1125%)Interim Dividend | 17 Oct, 2023 | 17 Oct, 2023 |
| 14 Mar, 2023 | Rs.21.0000 per share(1050%)Interim Dividend | 24 Mar, 2023 | 24 Mar, 2023 |
| 20 Apr, 2022 | Rs.10.5000 per share(525%)Final Dividend | 15 Sept, 2022 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 21 Feb, 2025 | BSE India | Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting |
| 31 Jan, 2025 | NSE India | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
| 31 Jan, 2025 | BSE India | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
| 30 Jan, 2025 | NSE India | Alivus Life Sciences Limited has informed the Exchange about Transcript |
| 29 Jan, 2025 | NSE India | Alivus Life Sciences Limited has informed the Exchange about Schedule of meet |
| 29 Jan, 2025 | BSE India | Please find attached herewith Analyst/investors meet intimation. |
| 23 Jan, 2025 | BSE India | Audio recording of Q3 FY2024-25 Earnings Call |
| 23 Jan, 2025 | NSE India | Alivus Life Sciences Limited has informed the Exchange about Link of Recording |
| 23 Jan, 2025 | BSE India | Please find attached herewith Integrated Filing (Financials) for the third quarter and nine months ended 31 December, 2024 |
| 23 Jan, 2025 | NSE India | Integrated Filing (financials) for the Third Quarter and Nine Months ended December 31, 2024 |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 17 Jan, 2025 | 23 Jan, 2025 |
| Quarterly Results | -- | 17 Oct, 2024 | 24 Oct, 2024 |
| Quarterly Results | -- | 19 Jul, 2024 | 25 Jul, 2024 |
| Audited Results | -- | 19 Apr, 2024 | 25 Apr, 2024 |
| Quarterly Results | -- | 16 Jan, 2024 | 23 Jan, 2024 |
| Quarterly Results | -- | 16 Oct, 2023 | 20 Oct, 2023 |
| Interim Dividend | -- | 05 Oct, 2023 | 09 Oct, 2023 |
| Quarterly Results | -- | 14 Jul, 2023 | 21 Jul, 2023 |
| Audited Results | -- | 20 Apr, 2023 | 27 Apr, 2023 |
| Interim Dividend | -- | 10 Mar, 2023 | 16 Mar, 2023 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Glenmark Life Sciences
Glenmark Life Sciences is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 2283.21 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
2011
Managing Director
Dr. Yasir Rawjee
NSE Symbol
GLS
Glenmark Life Sciences Management
| Name | Designation |
|---|---|
| Mr. Hiren K Patel | Chairman & Non-Exe.Director |
| Dr. Yasir Rawjee | Managing Director & CEO |
| Mr. Vinod Naik | Executive Director |
| Mrs. Manju Agarwal | Independent Director |
| Mr. Taruvai Laxminarayanan Easwar | Independent Director |
| Mr. Kaushikbhai N Patel | Independent Director |
| Mr. Vijaykumar Shah | Independent Director |
| Dr. Savan Godiawala | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Glenmark Life Sciences
What is the share price of Glenmark Life Sciences?
The share price of Glenmark Life Sciences on 21 Feb, 2025 is ₹ 1,022.05.
What is 52W high and 52W low share price of Glenmark Life Sciences?
The highest and lowest 52W share prices of Glenmark Life Sciences are ₹ 1335.000 and ₹ 647.100
What is the market cap of Glenmark Life Sciences?
The market capitalization of Glenmark Life Sciences as of 21 Feb, 2025 is ₹ 12,453.20 Crores
What is the P/E ratio of Glenmark Life Sciences?
The current P/E ratio of Glenmark Life Sciences as of 21 Feb, 2025 is 43.99
What is the PB ratio of Glenmark Life Sciences?
The PB ratio of Glenmark Life Sciences as of 21 Feb, 2025 is 5.34
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)